The primary aim of the Career Enhancement Program (CEP) is to attract and train exceptional investigators at City of Hope and University of Alabama Birmingham in conducting outstanding lymphoma translational research. Both junior and established researchers who desire to focus or refocus on lymphoma may participate. Two individuals are supported every year, for up to two years. Recruitment of investigators who wish to pursue a career in lymphoma research may also take place. SPORE has budgeted direct costs of $50,000 per year, with additional yearly contributions from City of Hope and UAB of $100,000 and $25,000, respectively. Investigators can use funds for salary support for protected research time, personnel and supplies, and meeting and training expenses. Drs. Stephen Forman, Alexandra Levine, and Smita Bhatia, collectively representing extensive mentoring experience, lead the CEP. They will direct the process of selecting trainees, providing advice and feedback, and coordinating an annual review. Program announcements are widely disseminated through various media to ensure awareness. A sustained, concerted effort will be made to attract women and minority candidates. Applicants are reviewed on the basis of their qualifications, the scientific merit and feasibility of their proposed project, and the potential for meaningful interaction with the other projects and cores within the SPORE. Trainees are to select mentors among senior faculty or SPORE members; the Career Enhancement Committee must approve the choice and is available for assisting the matching process. Trainees submit a written progress report twice annually, detailing relevant work to date and manuscripts and presentations that arose from their research. Awardees present their research at the annual SPORE retreat. The External Advisory Board evaluates progress and seeks solutions to points of concern if necessary. Previous CEP recipients have been greatly productive. Dr. Xiuli Wang conducted highly promising research on chimeric antigen receptor (CAR) T cells redirected with dual specificity for cytomegalovirus and CD19; this investigation has been promoted to a full project within the current SPORE. Dr. Elizabeth Budde performed studies that led to a CAR T cell trial directed against CD123 in acute myeloid leukemia, and she is now the clinical lead in Project 4 of the SPORE. Dr. Alex Herrera, now a basic SPORE leader in Project 3, has made significant progress studying biomarkers and outcome in patients who undergo cellular therapies; two main translational research projects are ongoing. We anticipate that the new class of investigators will continue the tradition of performing cutting-edge, transformative lymphoma research.

Public Health Relevance

The Career Enhancement Program supports -- scientifically as well as financially -- investigators who wish to devote their efforts to lymphoma research. The innovative projects proposed by outstanding scientists hold promise for developing needed therapies for patients with lymphoma, possibly extending to other malignancies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
2P50CA107399-11A1
Application #
9418468
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2018-09-01
Budget End
2019-08-31
Support Year
11
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Beckman Research Institute/City of Hope
Department
Type
DUNS #
027176833
City
Duarte
State
CA
Country
United States
Zip Code
91010
Herrmann, Andreas; Lahtz, Christoph; Nagao, Toshikage et al. (2017) CTLA4 Promotes Tyk2-STAT3-Dependent B-cell Oncogenicity. Cancer Res 77:5118-5128
Herrera, Alex F; Mei, Matthew; Low, Lawrence et al. (2017) Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation. J Clin Oncol 35:24-31
Kortylewski, Marcin; Moreira, Dayson (2017) Myeloid cells as a target for oligonucleotide therapeutics: turning obstacles into opportunities. Cancer Immunol Immunother 66:979-988
Herrera, Alex F; Armand, Philippe (2017) Minimal Residual Disease Assessment in Lymphoma: Methods and Applications. J Clin Oncol 35:3877-3887
Won, Haejung; Moreira, Dayson; Gao, Chan et al. (2017) TLR9 expression and secretion of LIF by prostate cancer cells stimulates accumulation and activity of polymorphonuclear MDSCs. J Leukoc Biol 102:423-436
Gibson, Christopher J; Lindsley, R Coleman; Tchekmedyian, Vatche et al. (2017) Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma. J Clin Oncol 35:1598-1605
Herrera, Alex F; Rodig, Scott J; Song, Joo Y et al. (2017) Outcomes after Allogeneic Stem Cell Transplantation in Patients with Double-Hit and Double-Expressor Lymphoma. Biol Blood Marrow Transplant :
Urak, Ryan; Walter, Miriam; Lim, Laura et al. (2017) Ex vivo Akt inhibition promotes the generation of potent CD19CAR T cells for adoptive immunotherapy. J Immunother Cancer 5:26
Zhang, Chunyan; Xin, Hong; Zhang, Wang et al. (2016) CD5 Binds to Interleukin-6 and Induces a Feed-Forward Loop with the Transcription Factor STAT3 in B Cells to Promote Cancer. Immunity 44:913-923
Beharry, Andrew A; Lacoste, Sandrine; O'Connor, Timothy R et al. (2016) Fluorescence Monitoring of the Oxidative Repair of DNA Alkylation Damage by ALKBH3, a Prostate Cancer Marker. J Am Chem Soc 138:3647-50

Showing the most recent 10 out of 88 publications